FibroGen sells China unit to AstraZeneca in deal worth $160 million
Feb 20 (Reuters) - FibroGen FGEN.O said on Thursday that it has sold its China unit to AstraZeneca AZN.L for about $160 million. (Reporting by Sneha S K; Editing by Shailesh Kuber) ((Sneha.SK@thomsonreuters.com;))
Recent news on Kyntra Bio
See all newsBrief: Kyntra Bio Appoints Andrew E. Singer, Mba To Its Board Of Directors
NASDAQ RESUMED AT 01:28 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:23 PM
Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kyntra Bio swings to profit in Q2 on deconsolidation of subsidiary